Organon & Co. strengthens LARC strategy with MIUDELLA license from Sebela Pharmaceuticals
Organon & Co. licenses MIUDELLA copper IUD. Explore what this means for hormone-free contraception and LARC competition. Read the analysis.
Organon’s NEXPLANON earns five-year approval: How this changes the LARC landscape
FDA approves NEXPLANON for five years of use with REMS program. Find out how this reshapes contraceptive access, safety, and policy impact.